Innovative drugs for hematological tumors: The therapeutic effect of venetoclax/venetoclax tablets

Venetoclax tablets are an oral anti-tumor targeted drug mainly used to treat certain types of leukemia, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). It works by inhibiting the function of BCL-2 protein and has cytotoxic activity on tumor cells that overexpress BCL-2, thereby promoting cancer cells to undergo programmed death.

In clinical trials and practical applications, venetex tablets have shown significant therapeutic effects. It can effectively control the disease, relieve the patient's uncomfortable symptoms, and prolong the patient's survival. Especially for patients who are elderly or unsuitable for intensive induction chemotherapy, venetoclax provides an effective treatment option.

However, treatment effects vary between individuals and may be affected by multiple factors, such as the patient's condition, age, physical condition, etc. Therefore, when using venetex tablets, doctors will develop a personalized treatment plan based on the patient's specific situation and closely monitor the patient's response and changes in condition.

The original drug of Venekra has been launched in China and has been included in Class B medical insurance. The price of 100mg*14 tablets per box may be around 2,000 RMB, while the Turkish version of the original drug sold overseas, with the specification of 100mg*112 tablets, costs more than 10,000 RMB per box (the price may fluctuate due to the exchange rate). There are also cheaper generic drugs of Venacla sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 100mg*120 tablets produced by a Bangladesh pharmaceutical factory is more than 4,000 yuan per box (the price may fluctuate due to the exchange rate).